A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

Inclusion Criteria:

Age >=18 years
For paclitaxel combination arms: histologically or cytologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease
For docetaxel combination arms: histologically or cytologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease or histologically documented advanced (Stage IV) or recurrent NSCLC
For participants with breast cancer: HER2-negative disease as defined by local clinical guidelines
Participants with NSCLC to be treated with docetaxel need to have received at least one prior anti-cancer treatment regimen in an advanced setting and to have docetaxel be considered appropriate treatment
Evaluable or measurable disease per response evaluation criteria in solid tumors (RECIST) v.1.1
Life expectancy >=12 weeks
Eastern cooperative oncology group (ECOG) performance status of 0 or 1 at screening
Adequate hematologic and end organ function
Use of highly effective form of contraception

Exclusion Criteria:

Prior anti-cancer therapy
Prior treatment with phosphoinositide 3-kinase (PI3K) inhibitor
Known significant hypersensitivity to any components of study treatment
Grade >=2 peripheral neuropathy
Type 1 or Type 2 diabetes
Grade >=2 hypercholesterolemia or hypertriglyceridemia
Congenital long QT syndrome
Active congestive heart failure or ventricular arrhythmia